VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications

Area of Science:

• Neurology
• Pharmacology
• Movement Disorders

Background:

• Tardive dyskinesia (TD) is a serious, potentially irreversible hyperkinetic movement disorder caused by dopamine receptor antagonists.
• Current treatments for TD lack long-term efficacy and robust symptom control.
• Newer vesicular monoamine transporter 2 (VMAT2) inhibitors have emerged as potential therapeutic options.

Purpose of the Study:

• To describe the pharmacologic modifications of deutetrabenazine and valbenazine, VMAT2 inhibitors.
• To explain how these modifications may impact clinical practice for tardive dyskinesia treatment.
• To review evidence and expert opinion on using these agents for TD.

Main Methods:

• Review of pharmacologic modifications of deutetrabenazine and valbenazine.
• Analysis of case series, observational studies, and clinical trials involving these agents in TD.
• Inclusion of expert opinion on clinical practice implications.

Main Results:

• Deutetrabenazine and valbenazine are VMAT2 inhibitors pharmacologically modified from tetrabenazine.
• These agents have been explored for tardive dyskinesia treatment, despite specific FDA-labeled indications.
• Evidence from various study types suggests potential benefits for TD symptom management.

Conclusions:

• Deutetrabenazine and valbenazine represent advancements in VMAT2 inhibitor therapy for tardive dyskinesia.
• Understanding their pharmacologic profiles is crucial for optimizing clinical application.
• Further research and clinical experience will refine their role in managing TD.